Everett Campbell
Family Medicine · Detroit, MINPI 1710046792
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$781
- AbbVie$598
- Lilly USA, LLC$567
- Pfizer$431
- Boehringer Ingelheim$415
- plus $4K from 30 others
What the payments were for
- Food & beverage$7,746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,181 |
| GSK | 53 | $781 |
| AbbVie(2 entities) | 28 | $598 |
| Lilly USA, LLC | 29 | $567 |
| Pfizer | 27 | $431 |
| Boehringer Ingelheim | 21 | $415 |
| Teva Pharmaceuticals USA, Inc. | 6 | $383 |
| Abbott | 5 | $336 |
| Exact Sciences | 12 | $245 |
| Otsuka America Pharmaceutical, Inc. | 10 | $233 |
| Boston Scientific | 4 | $214 |
| Amgen | 2 | $207 |
| Novartis | 8 | $202 |
| Novo Nordisk | 13 | $201 |
| Merck | 9 | $194 |
| Alnylam Pharmaceuticals Inc. | 4 | $187 |
| Bayer | 2 | $153 |
| Amarin Pharma, Inc. | 1 | $145 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Sanofi Pasteur Inc. | 2 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $122 |
| Modernatx, Inc. | 1 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $116 |
| Abiomed | 2 | $113 |
| Dexcom, Inc. | 3 | $75 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Lundbeck LLC | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Alk-abello, Inc | 1 | $21 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,746 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $62,582 |
| TrulicityDulaglutide | 52 | $60,239 |
| JardianceEmpagliflozin | 57 | $45,147 |
| EliquisApixaban | 27 | $20,231 |
| XareltoRivaroxaban | 31 | $19,804 |
| MounjaroTirzepatide | 14 | $19,053 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $17,332 |
| EntrestoSacubitril/Valsartan | 14 | $11,179 |
| JanuviaSitagliptin Phosphate | 12 | $10,961 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $9,612 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $8,741 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 201 | $8,143 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $5,740 |
| Famotidine | 89 | $5,593 |
| DilantinPhenytoin Sodium Extended | 15 | $4,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $567 | $79,29266 claims |
| Novo NordiskOzempic, Novolog | $201 | $64,37669 claims |
| Boehringer IngelheimJardiance | $415 | $45,14757 claims |
| PfizerEliquis, Dilantin | $431 | $24,28742 claims |
| NovartisEntresto | $202 | $11,17914 claims |
| MerckJanuvia | $194 | $10,96112 claims |
| GSKIncruse Ellipta | $781 | $9,61229 claims |
| AstraZenecaSymbicort | $1,181 | $3,96318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Detroit
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.